• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
VTRS

VTRS

Viatris Inc.

NASDAQHealthcareDrug Manufacturers - Specialty & GenericUS

USD15.56

-0.13 (-0.83%)

Rating:C+

Company Profile

CEO

Scott Andrew Smith

IPO Date

1980-03-17

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Exchange

NASDAQ

Country

US

Market Metrics

Open

$15.69

Prev. Close

$15.69

Day Low

$15.50

Day High

$15.72

52W Low

$8.44

52W High

$17.53

Market Cap

$18.12B

Volume

6.75M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

27.2%

Avg Negative

2.0%

Avg Neutral

70.9%

News Feed

ISCV Beat IJJ Over the Past Year. Here's Why That Gap Could Easily Reverse.

fool.com·5/27/2026·↑ positive

GLP-1 Drugs Powered IHE's Big Year. IXJ Is Playing a Longer Game.

fool.com·5/27/2026·↓ negative

FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy

zacks.com·5/19/2026·↑ positive

Here's Why Viatris (VTRS) is a Strong Momentum Stock

zacks.com·5/18/2026·↑ positive

U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain

prnewswire.com·5/18/2026·↑ positive

Why Viatris (VTRS) is a Top Value Stock for the Long-Term

zacks.com·5/13/2026·↑ positive

Viatris Inc. (VTRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com·5/12/2026·↑ positive

Why Viatris (VTRS) is a Top Growth Stock for the Long-Term

zacks.com·5/12/2026·↑ positive

Viatris: From Cost Story To Pipeline-Driven Re-Rating (Rating Upgrade)

seekingalpha.com·5/12/2026·↑ positive

Viatris: The Cigar Butt Got Smoked, But I'm Holding The Rating

seekingalpha.com·5/11/2026·↑ positive